Topical Finasteride Side Effects

Topical Finasteride Side Effects: What the Evidence Shows

Medically reviewed by [Reviewer Name, MD] | Last reviewed: August 2026 | Editorial policy

Note: No topical finasteride formulation is FDA-approved in the US as of 2026. All topical use is off-label or compounded. This page covers evidence from clinical trials only.

The theoretical advantage of topical finasteride over oral is reduced systemic exposure — and therefore potentially fewer systemic side effects. Clinical trial data support a more favorable systemic profile, though they do not eliminate systemic side effects entirely.

Side Effect Comparison: Topical vs. Oral

Side Effect	Oral Finasteride 1 mg (Kaufman 1998)	Topical Finasteride 0.25% (Piraccini 2022)
Decreased libido	~1.8%	<1% (comparable to placebo)
Erectile dysfunction	~1.3%	<1%
Ejaculation disorder	~1.2%	<1%
Scalp irritation / contact dermatitis	N/A	~2–4% (vehicle-related)
Serum DHT reduction	~70%	~15–25%

The lower serum DHT reduction (~15–25% vs. ~70%) is both the mechanism for reduced systemic side effects and a potential trade-off in efficacy. Current evidence suggests topical finasteride is effective but the long-term comparison to oral at matched DHT reduction levels is not fully established.

Local Scalp Reactions

The most common adverse effects specific to topical formulations are local and typically vehicle-related: erythema (redness), pruritus (itching), and dryness at the application site. These are more common with alcohol-based vehicles and typically resolve on their own or with formulation adjustment.